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RESEARCH ARTICLE
Positron Emission Tomographic Imaging of Copper
64– and Gallium 68–Labeled Chelator Conjugates of
the Somatostatin Agonist Tyr3-Octreotate
Jessie R. Nedrow, Alexander G. White, Jalpa Modi, Kim Nguyen, Albert J. Chang, and Carolyn J. Anderson
Abstract
The bifunctional chelator and radiometal have been shown to have a direct effect on the pharmacokinetics of somatostatin receptor
(SSTR)-targeted imaging agents. We evaluated three Y3-TATE analogues conjugated to NOTA-based chelators for radiolabeling with
64Cu and 68Ga for small-animal positron emission tomographic/computed tomographic (PET/CT) imaging. Two commercially
available NOTA analogues, p-SCN-Bn-NOTA and NODAGA, were evaluated. The p-SCN-Bn-NOTA analogues were conjugated to Y3-
TATE through b-Ala and PEG8 linkages. The NODAGA chelator was directly conjugated to Y3-TATE. The analogues labeled with
64Cu
or 68Ga were analyzed in vitro for binding affinity and internalization and in vivo by PET/CT imaging, biodistribution, and Cerenkov
imaging (68Ga analogues). We evaluated the effects of the radiometals, chelators, and linkers on the performance of the SSTR
subtype 2-–targeted imaging agents and also compared them to a previously reported agent, 64Cu-CB-TE2A-Y3-TATE. We found that
the method of conjugation, particularly the length of the linkage between the chelator and the peptide, significantly impacted tumor
and nontarget tissue uptake and clearance. Among the 64Cu- and 68Ga-labeled NOTA analogues, NODAGA-Y3-TATE had the most
optimal in vivo behavior and was comparable to 64Cu-CB-TE2A-Y3-TATE. An advantage of NODAGA-Y3-TATE is that it allows labeling
with 64Cu and 68Ga, providing a versatile PET probe for imaging SSTr subtype 2–positive tumors.
S OMATOSTATIN RECEPTORS are overexpressed on avariety of human neuroendocrine tumors and have
become an important target for molecular imaging. There
are five receptor subtypes; somatostatin receptor subtype 2
(SSTR2) is found in a variety of malignancies and has
become the target for molecular imaging radiolabeled
somatostatin analogues.1–9 Previous research has demon-
strated that somatostatin analogues can be labeled directly
with 18F and 124I or modified with bifunctional chelators,
allowing the incorporation of radiometals.10–12
The radiometals 64Cu and 68Ga have desirable char-
acteristics for use in positron emission tomographic (PET)
imaging. 64Cu (T1/2 5 12.7 hours; b
+ [17.6%] 653 keV;
b2 [38.4%] 579 keV) is ideal for tracers with slower
accumulation within the target site and clearance from
nontargeted tissues and is also a promising radiometal for
radiotherapy due to b2 emission.13 Gallium-68 (T1/2 5
67.7 minutes; b+ [87.7%] 1,899 keV) has become a more
widely used radiometal for PET imaging due to the
convenience of its production from a 68Ge/68Ga genera-
tor.14 In addition, the high-energy positron emitted by
68Ga has potential for Cerenkov luminescence imaging,
which can be monitored using simpler and less expensive
whole-animal optical imaging equipment.15,16
The choice of bifunctional chelator and radiometal has
been shown to have a direct effect on the pharmacokinetics
of SSTR-targeted imaging agents. The chelator NOTA and
its analogues form stable complexes with both 64Cu and
68Ga.17–19 The NOTA analogues NODAGA and p-SCN-
Bn-NOTA have three carboxylates available for radiometal
complexation after conjugation to peptides and proteins. Lin
and colleagues demonstrated that 68Ga-[Tyr3]-octreotide
modified with a NOTA analogue having three carboxylates
demonstrated greater accumulation in SSTR-positive xeno-
graft with superior pharmacokinetics than analogues with
more carboxylates.20 In addition, this analogue demon-
strated pharmacokinetics akin to the DOTA analogue but
with superior clearance from the liver.20 Fani and colleagues
From the Departments of Radiology, Pharmacology & Chemical Biology,
and Bioengineering, University of Pittsburgh, Pittsburgh, PA, and the
Department of Radiation Oncology, Washington University, St. Louis,
MO.
Address reprint requests to: Carolyn J. Anderson, PhD, Department of
Radiology, University of Pittsburgh, 100 Technology Drive, Suite 452,
Pittsburgh, PA 15219; e-mail: andersoncj@upmc.edu.
DOI 10.2310/7290.2014.00020
# 2014 Decker Intellectual Properties
Molecular Imaging, Vol 13, 2014: pp 1–13 1
radiolabeled NODAGA-LM3, a modified somatostatin
antagonist, with 64Cu and 68Ga and evaluated the effects of
the radiometal on their in vivo performance.21 The
accumulation in the SSTR-positive xenograft was similar
for both agents, but there were significant differences in the
clearance from the kidneys and pancreas.
Here we compare commercially available chelators, p-
SCN-Bn-NOTA and NODAGA, conjugated to the SSTR2-
targeted somatostatin agonist Y3-TATE and radiolabeled
with 64Cu and 68Ga. The rationale for comparing NOTA
analogues is to determine the effect of radiometal and
linkages of NOTA analogues on the in vivo performance
of the agonist, Y3-TATE, as this analogue has been
investigated in human studies.22–26 The NODAGA che-
lator was directly conjugated to Y3-TATE, whereas the p-
SCN-Bn-NOTA chelators were conjugated to Y3-TATE
through b-Ala and PEG8 linkages. The in vitro and in vivo
results were compared to evaluate the effects of the
radiometal, chelators, and linker. The NOTA conjugates
were compared to 64Cu-CB-TE2A-Y3-TATE, which pre-
viously showed high SSTR2-positive tumor uptake with
clearance through nontarget tissues.27,28
Materials and Methods
General
64Cu was purchased from Washington University School of
Medicine and University of Wisconsin School of Medicine and
Public Health. 68Ga (Eckert & Ziegler Isotope Products, Berlin,
Germany) was eluted directly to a Modular-Lab (Eckert &
Ziegler Isotope Products), concentrated on a Strata-X-C
column from Phenomenex (Torrance, CA), and the 68Ga-
eluate was collected by desorbing it with 0.8 mL of 0.01 M
HCl/98% acetone solution. HCT116 cells were provided by
Dr. Bert Vogelstein at Johns Hopkins University and were
transfected with SStr2 as previously described.29 S-2-(4-
isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic
acid (p-SCN-Bn-NOTA) was purchased from Macrocyclics
(Dallas, TX), and 2,29-(7-(1-carboxy-4-((2,5-dioxopyrrolidin-
1-yl)oxy)-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid
(NODAGA-NHS ester) was purchased from CheMatech
(Dijon, France). All other chemicals were purchased from
Sigma-Aldrich Chemical Co. (St. Louis, MO) or Fisher
Scientific (Pittsburgh, PA).
Synthesis of Y3-TATE Analogues
4,11-Bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hex-
adecane (CB-TE2A) conjugated to Y3-TATE was synthesized
as previously reported.29 The general protocol for peptide
synthesis of the conjugates used for this study has been
previously described.28,30 Briefly, the peptides were prepared
on a solid support by standard Fmoc procedures using a
preloaded Fmoc-Thr(Boc)-Wang resin. Fmoc deprotection
was achieved by washing the resin with 20% piperidine
DMF (five times) for 2 minutes, followed by washing the
resin three times with DMF. The carboxyl group was
activated using 2-(1H-benzotriazole-1-yl)-1,1,1,3-tetramethyl-
uronium hexafluorophosphate (HBTU) and di-isopropyl-
ethylamine (DIPEA) to couple the subsequent Fmoc-
protected amino acids. Cyclization of the peptide was
accomplished by treating the resin with Tl(TFA)3 in
dimethylformamide (DMF). Following cyclization, the
Fmoc was removed from D-Phe to expose the free amine.
The free amine was treated under three conditions to
provide the Y3-TATE analogues for this study. NODAGA-
Y3-TATE was prepared by treating the resin with
NODAGA-NHS (2 Eq) and N,N9-diisopropylethylamine
(DIPEA) (5 Eq) in DMF overnight. NOTA-PEG8-Y3-TATE
(NOTA-PEG8) was prepared by first treating the resin with
Fmoc-PEG8-CH2CH2-COOH following standard Fmoc
procedures. Following the deprotection, the resulting free
amine was treated with p-SCN-Bn-NOTA (1.5 Eq) and
DIPEA (6 Eq) dissolved in DMF and reacted overnight.
NOTA-b-Ala-Y3-TATE (NOTA-b-Ala) was prepared under
the same methods as NOTA-PEG8, with Fmoc-b-Ala used
as the linker instead of Fmoc-PEG8-CH2CH2-COOH. The
resins were washed, the individual peptides were cleaved,
and side chain–protecting groups were removed using a
trifluoroacetic acid (TFA) solution (90% TFA, 5% water,
5% triisopropylsilane). The cleaved peptides were precipi-
tated out of solution using ice-cold diethyl ether and washed
twice with diethyl ether. The peptides were dissolved in
10% acetic acid and purified using preparatory high-
performance liquid chromatography (HPLC), where sol-
vent A is 0.1% TFA in water and solvent B is 0.1% TFA in
acetonitrile. The HPLC purification was carried out on a
Phenomenex Jupiter 5u C18 300 A˚ semipreparative column
(250 3 10 mm, 5 microns) starting at 82% A held for
2 minutes, then a linear gradient to 65% A over 10 minutes,
followed by a linear gradient to 50% over 3 minutes and a
linear gradient to 10% A over 1 minute. This was held for an
additional minute followed by a linear gradient to 82% A
over 1 minute and held for 4 minutes. The solvent was
removed in vacuo to yield pure Y3-TATE analogues. The
Y3-TATE analogues (Figure 1) were characterized on a
Waters e2695/ LCT Premier XE LCMS: NODAGA-Y3-
TATE (C64H87N13O19S2), [M] calculated 1405.5683, found
1405.4971; NOTA-PEG8-Y3-TATE (C88H127N15O27S3),
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[MH]+ calculated 1922.8266, found 1923.0698; NOTA-b-
Ala-Y3-TATE (C72H95N15O19S3), [M] calculated 1569.6091,
found 1570.3997.
Synthesis of Cold Standards of Cu- and Ga-Y3-TATE
Analogues
Cold copper labeling was achieved by reacting 300 mg of each
of the NOTA-Y3-TATE analogues, 300 mL 10% acetic acid,
and 2 mg of copper acetate for 30 minutes at 95uC. Cold
gallium labeling was achieved under the same conditions using
gallium trichloride. The reaction solution was purified using
preparatory HPLC, where solvent A is 0.1% TFA in water and
solvent B is 0.1% TFA in acetonitrile. The HPLC purification
was carried out on a Phenomenex Jupiter 5u C18 300 A˚
semipreparative column (250 3 10 mm, 5 microns) starting at
97% A, a linear gradient to 3% A over 10 minutes, and then
held for an additional 7 minutes. This was followed by a linear
gradient to 97% over 1 minute and held for an additional
4 minutes. The desired peak was collected and solvent was
removed in vacuo to yield pure Cu- and Ga-NOTA-Y3-TATE
analogues. The Cu- and Ga-NOTA-Y3-TATE analogues were
characterized on a Waters (Milford, MA) e2695/LCT Premier
XE LCMS: Cu-NODAGA-Y3-TATE (C64H87CuN13O19S2),
[M] calculated 1467.103, found 1467.272; Ga-NODAGA-Y3-
TATE (C64H87GaN13O19S2), [M] calculated 1473.280, found
1473.163; Cu-NOTA-PEG8-Y3-TATE (C88H127CuN15O27S3),
[M] calculated 1983.751, found 1983.592;Ga-NOTA-PEG8-
Y3-TATE (C88H127GaN15O27S3), [M] calculated 1989.928,
found 1989.298; Cu-NOTA-b-Ala-Y3-TATE (C72H95CuN15
O19S3), [M] calculated 1631.331, found 1631.794; Ga-NOTA-
b-Ala-Y3-TATE (C72H95GaN15O19S3), [MH]+ calculated
1636.519, found 1636.989.
Radiolabeling
64Cu radiolabeling was achieved by reacting 2 to 2.5 mg of
each of the Y3-TATE analogues, 200 mL 0.4 M NH4OAc
(initial pH 7.0), and < 37 MBq of 64CuCl2 in 0.1 N
hydrochloric acid for 30 minutes at 95uC. The coordination
Figure 1. Structures of NOTA- and
CB-TE2A-Y3-TATE analogues.
64Cu and 68Ga-NOTA-Y3-TATE Analogues for PET/CT 3
of 68Ga was achieved under similar conditions. Two
micrograms of each Y3-TATE analogue, 200 mL 0.4 M
NH4OAc (initial pH 7.0) and< 37 MBq of 68GaCl3 in 0.1 N
hydrochloric acid/98% acetone solution were reacted for
30 minutes at 95uC in an open vial. 64Cu-CB-TE2A-Y3-
TATE was prepared as previously described.28 Quality
control of the radiolabeled peptides was performed on a
Waters 2489/1525 HPLC to determine radiolabeling yield.
Receptor Binding Assays
Membrane preparations of HCT116-SSTr2 cells were used
for binding assays, and assays were performed on Perkin-
Elmer Unifilter (Waltham, MA) 96-well, GF/B filtration
plates using previously described methods, with some
modifications.28,29,31 Membranes were diluted in binding
buffer (50 mM Tris-hydrochloride [pH 7.4]; 5 mM
MgCl2
.6 H2O; 0.1% bovine serum albumin; and 0.5 mg
of aprotinin, 200 mg of bacitracin, 10 mg of leupeptin, and
10 mg of pepstatin A per milliliter), and 15 mg of
membrane protein was used per well. Increasing concen-
trations of 64Cu-labeled Y3-TATE analogues were added to
membranes to measure total binding, and nonspecific
binding was determined by conducting the assay in the
presence of an excess of Y3-TATE. After incubation of the
membranes at room temperature for 2 hours, the medium
was removed and the membranes were washed twice with
200 mL of binding buffer. OptiPhase Super-Mix (50 mL;
PerkinElmer, Waltham, MA) was added to each well, and
bound activity was measured with a liquid scintillation and
luminescence counter (2450 Microbeta2, PerkinElmer). All
dissociation constant (Kd) values were estimated from
nonlinear curve fitting of bound peptide versus the sum of
the concentrations of 64Cu-Y3-TATE analogues and Y3-
TATE using Prism software (GraphPad, La Jolla, CA).
Competitive Binding Assay
Receptor binding affinities (Ki) of cold Cu- and Ga-labeled
NOTA-Y3-TATE analogues were calculated from half-
maximal inhibitory concentration (IC50) values determined
by a competitive binding assay using 64Cu-NODAGA-Y3-
TATE. Assays were performed on Unifilter 96-well, GF/B
filtration. Plates were prepared by adding the following, as
ordered, to each well: binding buffer, varying concentra-
tions of cold Cu- or Ga-NOTA-Y3-TATE analogues (0–
1,000 nM), 64Cu-NODAGA-Y3-TATE (final concentration
0.5 nM), and 15 mg of membrane protein. Membranes and
binding buffer were prepared as stated above in the receptor
binding assay. The plates were allowed to incubate for 3
hours at room temperature (incubation time was four times
the Koff of
64Cu-NODAGA-Y3-TATE; data not shown). The
cells were then washed twice with phosphate-buffered
saline, OptiPhase Super-Mix (50 mL; PerkinElmer) was
added to each well, and bound activity was measured with a
liquid scintillation and luminescence counter (2450
Microbeta2). The IC50 values were calculated by fitting the
quadruplicate data with nonlinear regression using
GraphPad Prism software. The Ki values were calculated
by using the Cheng-Prusoff equation.32
Internalization Studies
Internalization studies were performed as previously
described.27 Briefly, HCT116-SSTr2 cells were cultured in
McCoy’s 5A medium supplemented with 10% fetal bovine
serum, 1% pencillin-streptomycin-glutamine, and Zeocin
(1 mg/mL); cells were incubated at 37uC in a humidified 5%
CO2 atmosphere. Before each assay, aliquots of prepared 2 3
107 cells/mL were placed in a 12-well plate and incubated
overnight. The wells were prepared as previously described,27
and 64Cu-labeled Y3-TATE analogues (6 ng/10 mL) were
added to blocked and unblocked wells (n5 3). Blocked wells
were pretreated with 2 mg/10 mL of Y3-TATE and washed, and
new growth medium was added. The cells were allowed to
incubate for 10 minutes at 37uC. Following incubation, the
medium was collected in separate fractions; the surface bound
and the lysed cells were counted on a Packard Cobra II
automated gamma counter (Packard Instrument Company,
Downers Grove, IL). The total protein concentration in the
cell lysate was determined using the BCA Protein Assay
(Pierce Biotechnology, Rockford, IL). Internalized and sur-
face-bound fractions were expressed as fmol/mg of protein.
Biodistribution
All animal studies were conducted under protocols
approved by the University of Pittsburgh and Washington
University Institutional Animal Care and Use Committees
(IACUC). Biodistribution experiments were conducted as
previously described with some modifications.31 Briefly,
healthy NCr nude female mice (6–8 weeks, Taconic Labs,
Hudson, NY) bearing HCT116-SSTR2-positive tumors
were injected with 64Cu- and 68Ga-Y3-TATE analogues
(0.74–1.85 MBq) via the tail vein. Animals were sacrificed at
selected time points following the injection, and organs of
interest were removed, weighed, and counted on a
WIZARD2 gamma counter (PerkinElmer). In addition,
blocking studies were performed for 64Cu analogues at 4
hours where the mice were injected with 50 mg of Y3-TATE
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30 minutes prior to injection of the radiotracer, except
CB-TE2A-Y3-TATE, which was coinjected with 100 mg of
Y3-TATE at 4 hours. The percent injected dose per gram
(%ID/g) was calculated by comparison to a weighed, diluted
standard.
PET/CT Imaging
Imaging studies were performed using NCr nude female
mice (6–8 weeks, Taconic Labs) bearing HCT116-SSTR2
tumors either in the shoulder or flank. Mice were injected
with the 64Cu- and 68Ga-labeled Y3-TATE analogues (3.7–
8.4 MBq) via the tail vein. After probe injection, imaging
was performed at the following time points: 68Ga probes 5
1 hour, 64Cu probes5 1 and 4 hours. For tail vein injection
and throughout imaging, the mice were anesthetized with 2
to 3% isoflurane under oxygen at a flow rate of 2 L/min.
PET/CT imaging was performed on an Inveon small-animal
PET/CT scanner (Siemens Molecular Imaging, Knoxville,
TN) with the following parameters: 600-second PET
acquisition time, two-dimensional (2D) ordered subset
expectation maximization (OSEM) (standard uptake value
[SUV] calculations) and three-dimensional (3D) OSEM
(PET/CT images) reconstruction algorithms, CT-based
attenuation correction, voxel size 0.7 mm3; CT exposure
settings: 80 kV, 500 mA, 120 ms exposure time, 220u
rotation with 120 steps, low magnification, bin 4, voxel size
0.8 mm3; CT reconstruction: Shepp-Logan reconstruction
filter, bilinear interpolation, downsample factor 2, voxel size:
x 5 412.9 mm, y 5 412.9 mm, z 5 533.33 mm. 64Cu-CB-
TE2A-Y3-TATE was imaged as previously described at 2
hours postinjection.27,33,34 All PET images were manually
coregistered to the CT, analyzed, and prepared using the
Inveon Research Workplace software (Siemens Molecular
Imaging). PET images were exported as maximum intensity
projections, and final images were prepared using ImageJ
software (National Institutes of Health [NIH], Bethesda,
MD) and Adobe Photoshop CS5.
Cerenkov Luminescence Imaging
Following PET/CT imaging, mice injected with 68Ga-based
probes were placed into an IVIS Lumina XR optical
imaging station (PerkinElmer) to evaluate Cerenkov
luminescence in the tumors. Images were acquired using
the following parameters: no light acquisition filter,
acquisition time: 300 seconds, binning: 8 3 8, F/stop: 1,
field of view: 10 cm 3 10 cm. Animals were anesthetized
with 2% isoflurane under oxygen with a flow rate of
2 L/min throughout imaging and were heated by a 37uC
platform throughout imaging. Machine control was
performed using Living Image software version 3.1
(PerkinElmer). The 16-bit TIFF output images were
opened using ImageJ software, and outlier hotspots due
to cosmic radiation were removed using the ‘‘remove
outliers’’ tool. Images were then background subtracted
using the rolling ball algorithm (radius 5 500 pixels).
Free-hand regions of interest (ROI) were drawn around
the tumor and the leg opposite the tumor as a muscle
reference, and mean pixel intensities were measured within
each ROI. Tumor to muscle ratios were then calculated.
Image labels were added using Adobe Photoshop CS5.
Statistical Analysis
Prism version 5 software was used to determine p values
and statistical significance. An unpaired t-test was used to
compare biodistribution values presented in this article.
Results
Synthesis and Radiolabeling
Y3-TATE was prepared on resin as previously described.28,30
The terminal D-Phe was deprotected on the resin to expose
the free amine for incorporation of the NOTA chelators and
linkers. The free amine was modified to provide the chelator-
Y3-TATE analogues in the following yields: NODAGA-Y3-
TATE (1.9%), NOTA-b-Ala-Y3-TATE (2.1%), and NOTA-
PEG8-Y3-TATE (3.4%). These analogues were radiolabeled
in high yield and purity with 64Cu ($ 95%) and 68Ga
($ 99%). The specific activities ranged between 42.2 and
150.6 MBq/mmol (Table 1).
Receptor Binding Assays
A saturation binding assay was performed using HCT116-
SSTR2 membranes.31 The dissociation constant (Kd) for
64Cu-NODAGA-Y3-TATE (0.5 6 0.1 nM) was similar to
the previously reported values for 64Cu-CB-TE2A-Y3-TATE
(Table 2)29; however, the Bmax was greater for the CB-TE2A
analogue compared to the NODAGA analogue (4200 6
Table 1. Specific Activities (GBq/mmol) of NOTA Analogues at
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200 vs 2048 6 79.9 fmol/mg, respectively). Linker
modifications to p-SCN-Bn-NOTA significantly decreased
the affinity of the radiotracers (b-Ala analogue 1.8 6 0.7 nM;
PEG8 analogue: 2.3 6 0.9 nM; p # .05); in addition,
increasing the size of the linker resulted in lower Bmax values.
The use of the b-Ala linker demonstrated a slightly lower
Bmax (1660 6 190 fmol/mg) to the linker free NODAGA
analogue, whereas the use of the PEG8 linker greatly reduced
the Bmax (980 6 130 fmol/mg); p # .05).
Competitive Binding Assays
The IC50 values were determined in a competitive binding
assay using 64Cu-NODAGA-Y3-TATE as the radioligand
and HCT116-SSTR2 membranes (see Table 2). The
competitive binding assays were performed once, and the
Ki value was calculated from the IC50 using the Cheng-
Prusoff equation. Cu- and Ga-NODAGA-Y3-TATE pre-
sented the lowest Ki values for the NOTA analogues; both
analogues had a Ki of 0.6 nM. As seen with the dissociation
constants, the addition of linkers demonstrated an increase
in the Ki values. For the b-Ala linker, the cold Cu analogue
had a Ki of 1.5 nM, which was slightly lower than the Ga
analogue, with a Ki of 4.0 nM. The difference between the
Cu- and Ga-NOTA analogues was the greatest for NOTA-
PEG8-Y3-TATE: Cu-NOTA-PEG8-Y3-TATE (Ki 5 16 nM)
and Ga-NOTA-PEG8-Y3-TATE (Ki 5 2.5 nM).
Internalization Studies
Internalization studies were performed with HCT116-SSTR2
cells (Figure 2). 64Cu-NOTA-PEG8-Y3-TATE demonstrated
rapid internalization within 30 minutes, slightly increasing
over 4 hours (3460 6 130 fmol/mg). Unlike 64Cu-NOTA-
PEG8-Y3-TATE, the internalization of the b-Ala and
NODAGA analogues continued to significantly increase
over the 4-hour window, 64Cu-NOTA-b-Ala-Y3-TATE by
49% and 64Cu-NODAGA-Y3-TATE by 59% from the initial
15-minute time point. The addition of the blocking agent at
each time point reduced the uptake of all 64Cu-labeled
NOTA-Y3-TATE analogues, indicating that the internaliza-
tion was receptor mediated.
Biodistribution
Biodistribution studies were carried out in NCr nude female
mice (6–8 weeks) bearing HCT116-SSTR2 tumors. At
1 hour, all 64Cu and 68Ga analogues had high uptake in
the kidneys, pancreas, and SSTR2-positive tumors (Figure 3
and Figure 4). At 1 hour, the 64Cu- and 68Ga-labeled
compounds showed significant differences in kidney
uptake. The Ga-labeled NOTA analogues demonstrated
higher kidney uptake compared to the Cu-labeled analo-
gues, with the exception of the NODAGA-Y3-TATE. The
uptake in the pancreas for all analogues decreased to
background by 24 hours. Compared to the 64Cu- and 68Ga-
labeled NODAGA and PEG8 analogues, the
64Cu- and 68Ga-
labeled NOTA-b-Ala-Y3-TATE analogues exhibited signifi-
cantly higher uptake in the pancreas at 1 hour (p values #
.05), which decreased by 4 hours, presenting uptake similar
to that of the other analogues. Although the 68Ga-NOTA
analogues had greater %ID/g values at 1 hour compared to
the analogous 64Cu compounds, the differences were not
statistically significant (p values $ .1).
At 4 hours, 64Cu-NODAGA-Y3-TATE and 64Cu-CB-
TE2A-Y3-TATE demonstrated significantly higher uptake in
the tumor (15 6 4.8% and 13 6 3.1 %ID/g) than both the
PEG8 and b-Ala analogues (5.5 6 1.7 and 5.8 6 2.6 %ID/g;
p , .01). At 24 hours, 64Cu-NOTA-PEG8-Y3-TATE (5.2 6
1.2 %ID/g; p, .03) presented with the highest tumor uptake,
but uptake in the kidneys and liver was greater than in the CB-
TE2A, NODAGA, and b-Ala analogues. 64Cu-NODAGA-Y3-
TATE and 64Cu-CB-TE2A-Y3-TATE at 24 hours had the
highest tumor uptake (3.3 6 0.5 %ID/g; 3.3 6 0.3 %ID/g),
Table 2. Dissociation Constant, Bmax and Binding Affinity of NOTA and CB-TE2A Analogs
Copper-64 Copper* Gallium*
Kd (nM) Bmax (fmol/mg) Ki (nM) 95% CI Ki (nM) 95% CI
NODAGA-Y3-TATE 0.5 6 0.1 2050 6 80 0.6 0.3–1.3 0.6 0.2–2.4
NOTA-b-Ala-Y3-TATE 1.8 6 0.7 1660 6 186 1.5 0.1–30 4.0 0.1–195
NOTA-PEG8-Y3-TATE 2.3 6 0.9 984 6 126 2.5 0.1–53 16 3.1–87
CB-TE2A-Y3-TATE{ 0.5 6 0.1 4200 6 200 N/A
N/A 5 not available.
*Ki assays were preformed once with the cold standards of the NOTA-Y3-TATE analogues.
{Previously reported.29
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Figure 2. Internalization studies performed with 64Cu-labeled NOTA-Y3-TATE analogues using HCT116-SSTR2-positive colorectal carcinoma
cells (n 5 3). Blocking was achieved with cold Y3-TATE (n 5 3). (A) Internalized and (B) surface-bound 64Cu-NOTA-Y3-TATE analogues in
HCT116-SSTR2-positive cells with and without blocking.
Figure 3. Biodistribution of 64Cu-NOTA and CB-TE2A-Y3-TATE analogues at 1 hour, 4 hours, 4 hours blocked, and 24 hours in NCr nude mice
bearing HCT116-SSTR2 tumors (n 5 4 for each group).
64Cu and 68Ga-NOTA-Y3-TATE Analogues for PET/CT 7
with significant clearance from nontargeted organs. At 24
hours, 64Cu-NOTA-b-Ala-Y3-TATE showed the highest
uptake in the kidneys (3.0 6 0.3 %ID/g), followed by the
tumor (1.1 6 0.3 %ID/g).
Of all compounds evaluated, 64Cu-NODAGA-Y3-
TATE demonstrated superior tumor to blood/muscle
ratios for all time points; however, at 1 hour, the tumor
to blood/muscle ratio of 64Cu-NODAGA-Y3-TATE and
the tumor to muscle ratios of all the 64Cu-labeled NOTA
analogues at 4 hours were not statistically significant (p $
.07) compared to 64Cu-CB-TE2A-Y3-TATE (Table 3). For
the NOTA analogues, 68Ga- and 64Cu-labeled NODAGA-
Y3-TATE provided the highest tumor to blood/muscle
ratios. The tumor to muscle and tumor to blood ratios for
the 64Cu-labeled analogues were highest at 4 hours with
the exception of NOTA-PEG8-Y3-TATE, where the tumor
to muscle/blood ratios were similar at 1 and 4 hours (see
Table 3). 64Cu-CB-TE2A-Y3-TATE demonstrated the
highest tumor to muscle/blood ratios of all the analogues
at 1 hour (74 6 25 and 120 6 60, respectively). Of the
NOTA analogues at 1 hour, 64Cu-NODAGA-Y3-TATE
demonstrated the highest tumor to muscle/blood (73 6 78
and 58 6 26, respectively); however, it should be noted
that the differences in tumor to muscle ratios are not
statistically significant.
Blocking with unlabeled Y3-TATE demonstrated a
reduction in SSTR2-targeted agents for all compounds.
Preblocking caused a 90% decrease in tumor uptake of 64Cu–
NODAGA-Y3-TATE (1.8 6 0.5 %ID/g), a 76% decrease in
64Cu-NOTA-b-Ala-Y3-TATE (1.3 6 0.4 %ID/g), and a 61%
decrease in 64Cu-NOTA-PEG8-Y3-TATE (2.3 6 0.8 %ID/g).
64Cu-CB-TE2A-Y3-TATE (6.1 6 1.6 %ID/g) was coinjected
with Y3-TATE but still demonstrated reduced uptake in the
tumor by 54%. The decrease in tumor uptake when
preinjected or coinjected with Y3-TATE indicates selective
binding of SSTR2 for all analogues.
PET/CT Imaging
The PET/CT images for all the 64Cu and 68Ga Y3-TATE
analogues evaluated in this study (n5 2) had high contrast
for the tumor along with no-target uptake in kidneys and
bladder (Figure 5 and Figure 6), except 68Ga-NOTA-PEG8-
Y3-TATE (n 5 1), which had low contrast to nontarget
uptake. The nontarget uptake in the kidneys and bladder is
due to clearance of the PET agents. In comparing the 64Cu- or
68Ga-labeled analogues, it should be noted that there were no
significant differences in the SUV and tumor to muscle ratios.
The SUVs ranged between 0.48 and 4.0, with 64Cu-NOTA-b-
Ala-Y3-TATE demonstrating the highest SUV at 1 hour (4.0
6 0.6), and this agent and 64Cu-NODAGA-Y3-TATE had the
Figure 4. Biodistribution of 68Ga-NOTA-Y3-TATE analogues at
1 hour in NCr nude mice bearing HCT116-SSTR2-positive tumors
(n 5 4 for each group).
Table 3. Biodistribution Tumor to Blood/Muscle Ratios of NOTA and CB-TE2A Y3-TATE Analogues in HCT116 SSTR2-Positive
Tumor-Bearing Mice at 1, 4, and 24 Hours (n 5 4 for each group)
68Ga, 1 h 64Cu, 1 h 64Cu, 4 h 64Cu, 24 h
Tumor to Blood Muscle Blood Muscle Blood Muscle Blood Muscle
NODAGA-Y3-TATE 42 6 34 54 6 43 58 6 26* 73 6 78* 90 6 39 195 6 57* 36 6 2 100 6 15
NOTA-b-Ala-Y3-TATE 14 6 6{ 53 6 29{ 18 6 3 27 6 16 30 6 9 58 6 39* 13 6 3 28 6 15
NOTA-PEG8-Y3-TATE 5.8 6 2
{ 28 6 18{ 13 6 4 32 6 23 14 6 1 31 6 20* 10 6 3 29 6 11
CB-TE2A-Y3-TATE N/A N/A 74 6 25 120 6 60 251 6 58 220 6 173 122 6 18 366 6 225
N/A 5 not available.
*Not statistically significant (p values $ .07) compared to 64Cu ‘‘gold standard,’’ 64Cu-CB-TE2A-Y3-TATE.
{Not statistically significant (p values $ .07) compared to 68Ga-NODAGA-Y3-TATE.
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highest SUVs at 4 hours (3.1 6 0.5 and 3.1 6 0.9) (Table 4).
The 64Cu-labeled b-Ala and PEG8 NOTA-Y3-TATE analo-
gues demonstrated lower SUVs at 1 hour compared to the
NODAGA conjugate. 64Cu-NODAGA-Y3-TATE demon-
strated the second highest SUV (3.1 6 1.3) at 1 hour, whereas
64Cu-labeled NOTA-b-Ala-Y3-TATE (4.0 6 0.6) had the
highest, followed by the NODAGA, NOTA-PEG8 (2.6 6 0.6),
and CB-TE2A (2.2 6 0.6) analogues. At 1 hour, the tumor to
muscle trend was as follows: 64Cu-NODAGA-Y3-TATE (324
6 438) demonstrated the highest, followed by 64Cu-CB-
TE2A-Y3-TATE (34 6 16), 64Cu-NOTA-b-Ala-Y3-TATE (13
6 5.0), and 64Cu-PEG8-Y3-TATE (8.9 6 1.6). At 4 hours, the
trend reversed for the NOTA analogues, with 64Cu-PEG8-Y3-
TATE (38 6 3.4) having the highest and 64Cu-NODAGA-Y3-
TATE (26 6 2.1) the lowest.
68Ga-NODAGA-Y3-TATE demonstrated the highest
SUV of the 68Ga-labeled analogues (2 6 0.14). 68Ga-
NODAGA-Y3-TATE and 68Ga-NOTA-PEG8-Y3-TATE
(n 5 1) had similar tumor to muscle ratios compared
to 68Ga-NOTA-b-Ala-Y3-TATE (18 6 4.3, 15 and 9 6
7.2, respectively). 68Ga-NOTA-PEG8-Y3-TATE showed
the lowest tumor uptake of all compounds (SUV 5 0.5,
n 5 1; see Figure 6); however, the 64Cu agent had higher
uptake at 1 and 4 hours (2.6 6 0.6 and 1.9 6 0.4; see
Figure 5).
Cerenkov Imaging
To demonstrate the multimodal imaging utility of the
three 68Ga-based probes, the HCT116-SSTR2-positive
mice were also imaged by Cerenkov imaging in the
bioluminescence imaging scanner from 1.5 to 2 hours
following PET/CT. In mice imaged with 68Ga-NODAGA-
Y3-TATE, the tumor images showed good contrast with
minimal background other than the kidneys (Figure 7).
Due to the semiquantitative nature of this 2D technique,
exact values of uptake could not be calculated, but tumor
to muscle ratios were measured through ROI analysis of
the planar images generated by the Cerenkov emissions.
Following the same trend as PET imaging at 1 hour, 68Ga-
NODAGA-Y3-TATE showed a greater tumor to muscle
ratio than 68Ga-NOTA-b-Ala-Y3-TATE and 68Ga-NOTA-
PEG8-Y3-TATE (11 6 4, 4.4 6 7, and 4.4 [n 5 1]). It
should be noted that Cerenkov imaging was not attempted
on mice injected with 64Cu-based probes, because the
lower beta energy copper emissions produce significantly
Figure 5. PET/CT images of 64Cu-
NOTA-Y3-TATE analogues 1 hour
postinjection: NODAGA (6.1 MBq),
NOTA-b-Ala (2.4 MBq), NOTA-PEG8
(4.2 MBq). PET/CT image of 64Cu-CB-
TE2A-Y3-TATE 2 hours postinjection
(7.2 MBq). PET/CT images were per-
formed with NCr nude mice bearing
HCT116-SSTR2 tumors. Images are
maximum intensity projections and
rotated to achieve the best presentation
of the tumor.
Figure 6. PET/CT images of 68Ga-
NOTA-Y3-TATE analogues 1 hour post-
injection: NODAGA (5.2 MBq), NOTA-
b-Ala (4.6 MBq), NOTA-PEG8 (6.8
MBq). PET/CT images were performed
with NCr nude mice bearing HCT116-
SSTR2 tumors. Images are maximum
intensity projections and rotated to
achieve the best presentation of the
tumor; in the 68Ga-NOTA-PEG8-Y3-
TATE image, the tumor is circled due
to high activity in the bladder.
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less Cerenkov luminescence, and is not optimal for this
application.
Discussion
The choice of bifunctional chelator, linker between the
chelator and targeting molecule, and radiometal impacts
the performance of SSTR-targeted imaging agents. This
study focused on the incorporation of NOTA chelators to
Y3-TATE, a well-characterized agonist of SSTR2, in
comparison with CB-TE2A-Y3-TATE, which we previously
showed to have high image contrast for imaging a SSTR2-
positive tumor-bearing rat model.27,28 The NOTA chelator
was selected due to its ability to stably incorporate both
64Cu and 68Ga. In addition, NODAGA and p-SCN-Bn-
NOTA are commercially available analogues of NOTA that
when conjugated provide three carboxylates for N3O3
coordination.17–19,35–37 The NODAGA chelator was con-
jugated directly to the N-terminus of Y3-TATE, resulting in
an amide bond. NODAGA-Y3-TATE was previously
synthesized, labeled with 68Ga in high specific activity, and
evaluated in Rhesus monkey brain sections38,39; however, to
our knowledge, 68Ga- or 64Cu-labeled NODAGA-Y3-TATE
has not been evaluated in vivo, although NODAGA has
been evaluated with the SSTR2 antagonist LM3.21 In a
previously reported study, 64Cu-labeled NODAGA and CB-
TE2A conjugates of the SSTR2 antagonist LM3 were
compared, and the NODAGA analogue was deemed superior.
One of the goals of this study was to determine if this trend
was similar for the widely used SSTR2 agonist Y3-TATE. In
addition, we compared these agents to other NOTA-Y3-
TATE conjugates and evaluated them in an SSTR2-transfected
human cell line, SSTR2-positive HCT116,29 which can be
readily grown in nude mice and is a convenient model for
evaluating new radiolabeled SSTR2-targeted agents.
The p-SCN-Bn-NOTA chelate was conjugated using
two different linker groups; the linkers are necessary due to
the instability of the thiourea bond at the a-amine. The
placement of a thiourea directly on the a-amine of a
peptide can cause an Edman’s degradation, resulting in
removal of the terminal amino acid.40,41 The movement of
the thiourea away from the a-amine can increase the
stability of the thiourea when conjugated to a peptide.
Banks and Paquette demonstrated that the conjugation
through the e-amine of a lysine versus the a-amine was
Table 4. PET/CT Data of 68Ga and 64Cu NOTA-Y3-TATE and CB-TE2A-Y3-TATE Analogues in HCT116 SSTR2-Positive Tumor-
Bearing Mice (n 5 2 per group unless otherwise noted)
68Ga 1 h 64Cu 1 h 64Cu 4 h
SUV T:M SUV T:M SUV T:M
NODAGA-Y3-TATE 2.0 6 0.1 18 6 4.4 3.1 6 1.3 324 6 438 3.1 6 0.8 26 6 2.1
NOTA-b-Ala-Y3-TATE 0.81 6 1.0 8.5 6 7.2 4.0 6 0.6 13 6 4.9 3.1 6 0.5 29 6 34
NOTA-PEG8-Y3-TATE* 0.48 15 2.6 6 0.6 8.9 6 1.6 1.9 6 0.4 38 6 3.4
CB-TE2A-Y3-TATE{ N/A N/A 2.2 6 0.6{ 34 6 16{ N/A N/A
N/A 5 not available; PET/CT 5 positron emission tomography/computed tomography; SUV 5 standardized uptake value; T:M 5 tumor to muscle ratio.
*68Ga image analysis, n 5 1.
{PET/CT performed at 2 hours.
Figure 7. Cerenkov imaging 1.5 hours postinjection of 68Ga-
NODAGA-Y3-TATE (3.9 MBq) in NCr nude mice bearing HCT116-
SSTR2 tumors. Images were acquired for 300 seconds with binning:
8 3 8, F/stop: 1, field of view: 10 cm 3 10 cm. The 68Ga-NODAGA-
Y3-TATE Cerenkov image was selected due to its superior contrast
between the tumor and background compared to the b-Ala and PEG8
analogues.
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more stable after 10 days at 37uC.42 Cooper and colleagues
demonstrated that p-SCN-Bn-NOTA conjugated through
the side chain on lysine forms a stable thiourea bond with
no difference in the in vivo stability compared to an amide
conjugated chelator.19 The b-Ala was selected to maintain
a probe similar in size to the NODAGA and CB-TE2A
analogues, whereas the PEG8 linker was selected to analyze
the effects of linker length on the probe’s performance.
The 64Cu analogues were evaluated in vitro by saturation
binding, competitive binding, and internalization assays
using HCT116-SSTR2-positive cells. 64Cu/Cu-NODAGA-
Y3-TATE (Kd 5 0.5 6 0.1 nM; Ki 5 0.6 nM) demonstrated
the highest binding affinity, similar to 64Cu-CB-TE2A-Y3-
TATE (Kd 5 0.5 6 0.1 nM). The addition of p-Bn-SCN-
NOTA through the b-Ala and PEG8 linkages decreased the
affinity slightly (Kd5 1.8 6 0.7 nM [Ki5 1.5 nM] and Kd5
2.3 6 0.9 nM [Ki 5 2.5 nM], respectively). The effect of the
linker on affinity is mirrored in the cold gallium analogues as
well: Ga-NODAGA-Y3-TATE (Ki 5 0.6 nM), Ga-NOTA-b-
Ala-Y3-TATE (Ki 5 4.0 nM), and Ga-NOTA-PEG8-Y3-
TATE (Ki 5 16 nM). Similar to the results presented here,
Rogers and colleagues noted a decrease in affinity with a
PEGylated bombesin analogue compared to analogues with a
smaller linker.43 Furthermore, the increase in linker length
resulted in a reduced number of binding sites (Bmax) of the
64Cu-labeled analogues. We hypothesize that the larger PEG
linkage created steric hindrance for binding of additional Y3-
TATE-targeted agents by blocking potential binding pockets
of SSTR2. 64Cu-NOTA-PEG8-Y3-TATE had the lowest Bmax,
whereas the Bmax of
64Cu-NODAGA-Y3-TATE and 64Cu-
NOTA-b-Ala-Y3-TATE were comparable. However, the Bmax
of 64Cu-CB-TE2A-Y3-TATE was twofold higher than both
analogues. 64Cu-NOTA-PEG8-Y3-TATE also demonstrated
the lowest uptake and internalization in SSTR2-transfected
HCT116 cells, with 64Cu-NODAGA-Y3-TATE and 64Cu-
NOTA-b-Ala-Y3-TATE having similar, more superior inter-
nalization profiles. The in vitro results suggest that the linker
length between the chelator and the peptide had an impact on
their binding affinity and number of bound receptor sites.
The use of the smaller b-Ala linker to maintain a similar
linker length between the chelator and peptide when
compared to direct conjugation appeared to have little to
no effect on the in vitro performance of the radiotracers.
Based on the in vitro results we expected that the in vivo
performance of NODAGA-Y3-TATE, NOTA-b-Ala-Y3-
TATE, and CB-TE2A-Y3-TATE would be similar, whereas
larger NOTA-PEG8-Y3-TATE would be less optimal. The
tumor uptake and nontargeted organ clearance of 64Cu-
NODAGA-Y3-TATE and 64Cu-CB-TE2A-Y3-TATE were
comparable; however, 64Cu-CB-TE2A-Y3-TATE had a
higher tumor to blood ratio at 4 hours. 64Cu-CB-TE2A-
Y3-TATE demonstrated superior tumor to muscle/blood
ratios over the NOTA analogues in the biodistribution
studies at 1, 4, and 24 hours, except at 1 hour, where the
tumor to blood/muscle ratio of 64Cu-NODAGA-Y3-TATE
and all tumor to muscle ratios of 64Cu-labeled NOTA
analogues at 4 hours were not statistically significant (p $
.07). When comparing 64Cu-NODAGA-Y3-TATE and
64Cu-CB-TE2A-Y3-TATE to the -b-Ala and -PEG8 p-
SCN-NOTA analogues, it is clear that the length of the
linker significantly affected the in vivo performance. The
increased linker length of 64Cu-NOTA-PEG8-Y3-TATE likely
resulted in significantly higher (p# .05) uptake in the tumor
at the 24-hour time point but with higher accumulation in
the kidneys and liver at the 4- and 24-hour time points
compared to the other analogues. The use of a small linker in
64Cu-NOTA-b-Ala-Y3-TATE demonstrated tumor uptake
comparable to 64Cu-NODAGA-Y3-TATE and 64Cu-CB-
TE2A-Y3-TATE at 1 hour; however, washout from the
tumor occurred rapidly, with a significant reduction in
tumor uptake at 4 and 24 hours. The superior in vivo
performances of the similar-sized 64Cu-NODAGA-Y3-TATE
and 64Cu-CB-TE2A-Y3-TATE suggest that direct conjuga-
tion of Y3-TATE to the a-amine provides a favorable
interaction with SSTr2, resulting in increased uptake and
retention in the SSTR2 tumor. This is further supported by
the performance of the a-conjugated 68Ga-NODAGA-Y3-
TATE, which had superior tumor to muscle/blood ratios in
the biodistribution studies and tumor to muscle ratios in
both PET/CT and Cerenkov imaging when compared to the -
b-Ala and -PEG8 analogues. It should be noted that there
were significant differences between the 64Cu- and 68Ga-
labeled analogues with respect to the kidney uptake. We
hypothesize that this is a result of differences in the overall
charge of these chelated metals (64Cu:21; 68Ga: neutral). The
differences in the kidney uptake should be considered when
selecting an imaging agent to minimize the radiation dose
delivered to the kidneys. Finally, the choice of the radiometals
(64Cu and 68Ga) with the exception of kidney uptake in the
evaluation of the Y3-TATE analogues through biodistribu-
tion studies, PET/CT, and Cerenkov imaging did not
demonstrate a significant impact on in vivo performance of
the NOTA analogues.
Conclusion
Commercially available analogues of NOTA were investi-
gated for radiolabeling with 64Cu and 68Ga for SSTR2-
targeted PET/CT imaging. The size and method of
conjugation had a greater impact on the performance of
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these SSTR2-targeted PET agents than changes in radio-
metal, which were determined insignificant. Direct con-
jugation of a NOTA chelator to the a-amine of Y3-TATE
(NODAGA-Y3-TATE) demonstrated superior in vivo
performance for 64Cu- and 68Ga-labeled analogues com-
pared to the chelator conjugated through a linker. The in
vivo performance of 64Cu-NODAGA-Y3-TATE was com-
parable to 64Cu-CB-TE2A-Y3-TATE, one of the gold
standard agents that has been investigated in other SSTR2-
positive tumor models. Although 64Cu-CB-TE2A-Y3-
TATE was superior to 64Cu-NODAGA-Y3-TATE in tumor
to blood ratios at 4 hours, an advantage of NODAGA-Y3-
TATE is that this agent allows for incorporation of both
64Cu and 68Ga, incorporates 64Cu in high radiolabeling
yields in a shorter period of time than 64Cu-CB-TE2A-Y3-
TATE, and provides a versatile PET probe for imaging
SSTR2-positive tumors.
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